HELP Cybin Inc.

P/E --
Forward P/E --
Price/Sales 16436.36
Beta 0.705
Div Yield --
Market Cap --

Company Analysis

Latest News

🟢 HELP is trading 11% up today after $50M equity offering to fund drug pipeline

HELP is trading 11% up at $5.65 after announcing a $50 million underwritten public offering of common shares to advance its mental health drug pipeline. • The...

🟢 HELP soars 5.7% after announcing US$50 million underwritten offering

• Helus Pharma (HELP) announced a US$50 million underwritten public offering of 10,309,280 common shares priced at $4.85 per share on June 24, 2026. • The...

🟢 HELP makes sharp 10.1% jump

HELP is trading at $5.34, up 10.1% versus the comparison close of $4.85 during regular trading. This is a price-movement alert; no separate company-specific...

🟢 HELP is trading 9.3% up today after pricing $50M offering to fund Phase 3 trial

HELP is trading 9.3% up now at $5.30 after the company priced a $50 million underwritten public offering at $4.85 per share. • The capital raise will fund...

Helus Pharma Raises $50 Million Selling Stock at a Discount — But Can the Cash Get Its Depression Drug Across the Finish Line?

Helus Pharma Raises $50 Million Selling Stock at a Discount — But Can the Cash Get Its Depression Drug Across the Finish Line?

Shares shifted as Helus Pharma (Nasdaq: HELP), formerly known as Cybin, priced a US$50 million underwritten public offering just hours before its lead...

🟢 HELP makes sharp 10.7% jump

HELP is trading at $5.37, up 10.7% versus the comparison close of $4.85 during pre-market. This is a price-movement alert; no separate company-specific...

🟢 HELP is trading 9.1% up today after pricing a $50M public offering

HELP is trading 9.1% up at $5.29 in pre-market action after announcing a $50 million underwritten public offering priced at $4.85 per share. • The financing...

🟢 Cybin Inc. is trading 5.9% up today after analysts issued a 'Strong Buy' consensus rating

Cybin Inc. is trading 5.9% up today at $4.54 following a 'Strong Buy' consensus rating from analysts as of June 17, 2026. • Analysts have set a price target...

🟢 Cybin Inc. is trading 5.7% up today amid a broad market rebound

Cybin Inc. is trading at $4.28 (+5.68%) as the stock gains momentum following a broader market recovery. • Major U.S. indexes are trading higher, providing...

🟢 Cybin Inc. is trading 5.7% up today tracking a broad market rebound

Cybin Inc. is trading 5.7% up at $4.09 as it tracks a broad market rebound and recovers from several consecutive down sessions. • Major U.S. indices are...

🟢 Cybin Inc. is trading 5.4% up today as broader market futures rise

Cybin Inc. is trading 5.4% up at $4.08 in pre-market, rebounding from recent weakness and tracking broader market gains. • The stock is recovering from...

Helus Pharma Plummets 50% on CEO Exit, Awaiting Major Depression Data

Helus Pharma Plummets 50% on CEO Exit, Awaiting Major Depression Data

Helus Pharma (formerly Cybin Inc.) shares have dropped more than 50% following the unexpected departure of CEO Michael Cola in April 2026. Co-founder and...

🔴 Cybin Inc. is trading 5.9% down today amid a broad market risk-off session

Cybin Inc. is trading at $3.77 (-5.86%) as the stock extends its recent slide during a broad market risk-off session where speculative growth names are under...

🟢 Cybin Inc. is trading 6% up today on a technical rebound after recent weakness

Cybin Inc. is trading 6% up at $4.25 in pre-market sessions as the stock stages a technical rebound following recent downward pressure. • The move appears to...

🟢 Cybin Inc. is trading 6% up today as it rebounds from recent weakness

Cybin Inc. is trading 6% up at $4.25 in pre-market, rebounding from recent weakness following several consecutive down sessions last week. • The move lacks a...